618900-69-9

Basic information

• Product Name: ethyl 4-[(3-nitro-2-pyridyl)amino]piperidine-1-carboxylate
• Synonyms: Ethyl 4-[(3-nitropyridin-2-yl)amino]piperidine-1-carboxylate
• CAS NO: 618900-69-9
• Molecular Formula: C₁₃H₁₈N₄O₄
• Molecular Weight: 294.31
• Mol File: 618900-69-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 459°C at 760 mmHg
• Flash Point: 231.4°C
• Density: 1.327g/cm³
• Vapor Pressure: 1.31E-08mmHg at 25°C
• Refractive Index: 1.602
• CAS DataBase Reference: ethyl 4-[(3-nitro-2-pyridyl)amino]piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-[(3-nitro-2-pyridyl)amino]piperidine-1-carboxylate(618900-69-9)
• EPA Substance Registry System: ethyl 4-[(3-nitro-2-pyridyl)amino]piperidine-1-carboxylate(618900-69-9)

Safety Data

• Hazardous Substances Data: 618900-69-9(Hazardous Substances Data)

Upstream product

• 58859-46-4 ethyl 4-aminopiperidine-1-carboxylate 
• 1480-87-1 2-fluoro-3-nitropyridine 
• 5470-18-8 2-Chloro-3-nitropyridine 

Downstream Products

• 107618-03-1 1-piperidin-4-yl-1,3-dihydroimidazo[4,5-b]pyridin-2-one 
• 107618-22-4 ethyl 4-(3-aminopyridin-2-ylamino)piperidine-1-carboxylate 

Relevant articles and documents

Imidazopyridine derivatives as PI3K inhibitors

New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks)

1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine

The present invention discloses the compound of Formula I and pharmaceutically acceptable salts and solvates thereof. The invention also relates to pharmaceutical compositions comprising the Compound of Formula I and its use in treating obesity, metabolic syndrome, diabetes, hepatic lipidosis or nonalcoholic fatty liver disease. The invention also relates to the use of a combination of the Compound of Formula I with additional therapeutic agents for treating obesity, metabolic syndrome, diabetes, hepatic lipidosis or nonalcoholic fatty liver disease.

Synthesis and neuroleptic activity of a series of 1-[1-(benzo-1,4-dioxan-2-ylmethyl)-4-piperidinyl]benzimidazolone derivatives

-